Eculizumab for atypical hemolytic-uremic syndrome

New England Journal of Medicine

Volumn 360, Issue 5, 2009, Pages 542-544

  Nürnberger, Jens ^a   Witzke, Oliver ^a   Saez, Anabelle Opazo ^a   Vester, Udo ^a   Baba, Hideo Andreas ^a   Kribben, Andreas ^a   Zimmerhackl, Lothar Bernd ^b   Janecke, Andreas R ^b   Nagel, Mato ^c   Kirschfink, Michael ^d  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Center for Nephrology and Metabolic Disorders   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; HAPTOGLOBIN; TACROLIMUS; CFHR1 PROTEIN, HUMAN; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; DIALYSIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; GENETIC ANALYSIS; GRAFT FAILURE; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; LABORATORY TEST; LETTER; MISSENSE MUTATION; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE DRUG DOSE; TREATMENT OUTCOME; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; GENE DELETION; GENETICS; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT C5; COMPLEMENT FACTOR H; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MUTATION, MISSENSE; RECURRENCE; SEQUENCE DELETION;

EID: 59449107473     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0808527     Document Type: Letter

References (5)

1. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2008 September 18 (Epub ahead of print).
2. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267-79.
3. Brown KM, Sacks SH, Sheerin NS. Mechanisms of disease: the complement system in renal injury - new ways of looking at an old foe. Nat Clin Pract Nephrol 2007;3:277-86.
4. Hillmen P, Hall C, Marsh JCW, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9.
5. Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H- related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007;3(3):e41.